| Title |
Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
|
|---|---|
| Published in |
Trials, October 2020
|
| DOI | 10.1186/s13063-020-04747-8 |
| Pubmed ID | |
| Authors |
Mehdi Hassaniazad, Ali Bazram, Soheil Hassanipour, Mohammad Fathalipour |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 177 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 177 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 18 | 10% |
| Student > Master | 16 | 9% |
| Researcher | 13 | 7% |
| Student > Ph. D. Student | 12 | 7% |
| Other | 11 | 6% |
| Other | 32 | 18% |
| Unknown | 75 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 23% |
| Nursing and Health Professions | 16 | 9% |
| Psychology | 9 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 4% |
| Social Sciences | 5 | 3% |
| Other | 22 | 12% |
| Unknown | 78 | 44% |